569results about How to "Reduce recurrence" patented technology

Provided herein are compounds useful for the treatment of HBV infection in man.

The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN®.

The present invention is directed to a combination treatment of an opioid antagonist e.g., naltrexone and a second compound selected from the group consisting of a GABA B agonist, an NMDA antagonist, a serotonin antagonist, and a cannabinoid antagonist is the key to the successful treatment of a brain reward system disorder. A brain reward system, include but are not limited, to pathological gambling, compulsive alcohol consumption, compulsive over-eating and obesity, compulsive smoking, and drug addiction. The compounds and methods of the present invention effectively reduce the cravings, withdrawal symptoms and negative drug side effects associated with a monotherapy. As such, patient compliance is greatly increased, thereby decreasing relapse of a brain reward system disorder.

Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising administering to an individual in need thereof a therapeutically effective amount of ASBTI or a pharmaceutically acceptable salt thereof.

A sensor device for detecting product quality conditions is attached to each product to be delivered, and constant monitoring is performed on quality conditions of stock products in a storage room of a delivery center for quality assurance. For products in a storage room of a delivery truck, constant monitoring is also performed on quality conditions thereof in the same manner. If a quality abnormality is found in a product in the storage room, information regarding product sensing items and information regarding the current location of each delivery truck are processed to select a replacement stock product less susceptible to recurrence of a similar quality abnormality at the time of redelivery.

Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy.

Embodiments of the present invention relate to a method for delivering pharmaceuticals to the lens of the eye to treat or prevent presbyopia. According to the embodiments, pharmaceuticals may be applied by providing the pharmaceuticals to the eye and promoting delivery of the pharmaceuticals into the lens capsule and/or lens fibers of the lens of the eye. Methods include iontophoresis, nano-medication, and photonic activation to deliver the pharmaceuticals to treat or prevent presbyopia.

The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors. The compounds provided interfere with the binding of SDF1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis.

The invention belongs to the technical field of biology, and discloses a polypeptide containing two chimeric antigen receptor structures, nucleic acid for coding the polypeptide, a modified T lymphocyte, and a preparation method and application of the T lymphocyte. The polypeptide provided by the invention contains the two chimeric antigen receptor (CAR) structures, wherein one chimeric antigen receptor structure specifically targets a tumor cell, and the other one specifically targets a normal B lymphocyte, so that a CAR-T cell is effectively amplified through recognizing the B lymphocyte ofa blood circulation system, and more CAR-T cells arrive at a solid tumor part so as to specifically kill the tumor cell for improving a treatment effect on the solid tumor. The polypeptide further comprises an ScFv structure of an anti-PD-L1 monoclonal antibody, and the CAR-T cells can simultaneously secrete a PD-L1 monoclonal antibody which interdicts an immunosuppressive action medicated by a PD1/PDL1 signal pathway and T cell failure, so that the treatment effect on the solid tumor is improved, the functional activity of immune cells in vivo is prolonged at the same time, and finally the tumor recurrence is retarded and even avoided.

The invention provides a manufacturing method for an individualized lip and tongue side orthodontic appliance. According to the manufacturing method, the individualized lip and tongue side orthodontic appliance is manufactured according to a lip and tongue side shape of teeth of a patient; a manufactured bracket is divided into two parts; one part is a bracket body of the bracket; the other part of the bracket is an individualized bracket bottom plate of the bracket. The bracket body of the bracket in the orthodontic appliance contains three-dimensional data (whole tooth axis inclined degree, whole tooth torque and whole tooth convexity) of countryman normal whole teeth (dental crowns and tooth roots) reference values. Meanwhile, the designed bracket bottom plate is completely fitted with a lip and tongue side face of the teeth and the bonding strength of the bottom plate and the lip and tongue side face is enhanced. According to the manufacturing method, the whole teeth can be moved to one accurate position to realize the controllable quantitative movement of the whole position of the teeth; the tooth roots are placed on an ideal position; the requirements of special crowd are met and the reoccurrence after the correction is reduced; the occurrence rate of complications including bone exposure, bone fracture and the like is avoided, and the balance and the stability of the orthodontic effect is realized.

The present disclosure relates to methods and compositions to ameliorate or treat at least one symptom of colorectal cancer and/or adenomatous polyposis coli (APC). For example, some embodiments of the methods and compositions may reduce recurrence of colorectal adenomas and/or extend the life of a subject having colorectal cancer and/or APC. Some embodiments of the disclosure include maintaining a the total body weight in a subject having colorectal cancer and/or APC. According to some embodiments, a method of the disclosure may include administering a bile acid composition to a subject. A bile acid composition may include, in some embodiments, an aqueous solution that is free or substantially free of precipitates or particles. A aqueous solution may include (1) a bile acid, an aqueous soluble derivative of a bile acid, a bile acid salt, and/or 7-ketolithocholic acid, (2) a carbohydrate, and (3) water. An aqueous composition may further include an alkali.

Age-related macular degeneration (AMD) results in the formation of new blood vessels in the eye. The walls of these vessels leak fluid, which causes scarring in the surrounding tissue, resulting in reduced vision or loss of vision. Photodynamic therapy (PDT) alone has been used to treat AMD, but many retreatments are needed, which cause further damage to the already diseased area. Laser treatment to coagulate the fluid actually causes additional new vessels to form. However, the inventive method of treating patients with both PDT and laser coagulation surprisingly either improved vision, or prevented further loss of vision. Moreover, the combined treatment eliminated the need for retreatment, and did not generate new vessel growth. Laser coagulation and PDT may be administered within the same treatment session or either may be administered first and the other may be administered within ninety days.

The present invention relates to nucleic acid molecules containing poly (dA:dT) regions which are stabilized in E. coli, methods of propagating such nucleic acid molecules in E. coli, methods of obtaining RNA, peptides or proteins using such nucleic acid molecules and to RNA which is obtained from such nucleic acid molecules and its use. In particular, the poly (dA:dT) regions contain at least one disruption by a sequence not encoding a sequence solely composed of A residues.

An apparatus and methods for performing ablation of myocardial tissues are disclosed. The apparatus includes a plurality of ablation electrode configurations to which nanosecond pulsed electric fields are applied. The methods relate to therapies to treat cardiac arrhythmias, such as, atrial fibrillation and scar-related ventricular tachycardia, amongst others. The affected myocardial tissues are ablated creating a plurality of lesions enabled by the nanosecond pulsed electric fields applied to either penetrating electrodes, endo-endo electrodes, or endo-epi electrodes. Different electrophysiological tests are performed to assess the application of nanosecond pulsed electric field ablation to specific desired tissue location within the heart. Test results show the potential to overcome limitations of current ablation therapies, thereby providing patients and doctors a superior treatment for cardiac arrhythmias.

The present invention relates to compositions, methods and apparatuses for locating a nerve during a surgical procedure.

Disclosed is a method of promoting smoking cessation in a human comprising administration to the human an effective amount of reboxetine in combination with the administration of a smoking-cessation enhancing agent. Also disclosed is a composition for administration to a human for promoting smoking cessation comprising reboxetine and smoking-cessation enhancing agent. Examples of the smoking-cessation enhancing agents include nicotine, an antidepressant, a nicotine receptor antagonist, and an opioid antagonist.